Novavax NVAX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$87.84M-120% | $440.3M+28.8% | $341.75M-19.2% | $422.82M-11.7% | $478.7M+355% | ||
| $22.34M-19.1% | $27.61M-21.1% | $35.01M-14.9% | $41.12M-8.0% | $44.69M-7.9% | ||
| $33.45M-7.1% | $36.02M-6.4% | $38.5M-8.3% | $42M-10.4% | $46.88M-2.6% | ||
| $98.46M+0.3% | $98.19M+0.8% | $97.39M+27,805% | $349K— | $0-100% | ||
| —— | —— | —— | —— | —— | ||
| -$170.8M+47.1% | -$322.57M+6.1% | -$343.49M-8.4% | -$316.96M+9.0% | -$348.34M+14.8% | ||
| —— | —— | -$113.89M— | —— | —— | ||
| —— | —— | —— | —— | $2.57M-89.1% | ||
| -$69.9M+88.8% | -$622.94M— | —— | —— | —— | ||
| —— | —— | —— | -$630.94M-233% | -$189.21M-117% | ||
| $5.36M-5.7% | $5.69M+2.6% | $5.54M+13.2% | $4.9M-37.0% | $7.77M-40.5% | ||
| —— | —— | —— | —— | —— | ||
| $458.02M+29.5% | $353.74M-40.4% | $593.07M-0.9% | $598.18M+22.9% | $486.55M+9.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $8.45M-16.1% | $10.07M+53.7% | $6.55M+7.8% | $6.08M+4.2% | $5.84M+46.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$3.08M-235% | $2.29M+140% | -$5.78M+26.0% | ||
| -$59.93M+80.3% | -$303.62M+5.0% | -$319.61M+25.1% | -$426.58M-96.2% | -$217.46M-465% | ||
| $18.54M+23.2% | $15.05M-29.0% | $21.19M+4.9% | $20.2M+5.4% | $19.17M+9.1% | ||
| $9.15M+4.0% | $8.81M-3.3% | $9.11M+39.7% | $6.52M+159% | $2.52M+165% | ||
| —— | $0-100% | $12.99M-50.0% | $25.97M-33.3% | $38.96M-25.0% | ||
| —— | —— | —— | —— | $3.1M-25.0% | ||
| -$69.9M+88.8% | -$622.94M— | —— | —— | —— | ||
| —— | —— | -$113.89M— | —— | —— | ||
| —— | —— | —— | —— | $2.57M-89.1% | ||
| $1.67M-14.2% | $1.95M-35.2% | $3M-22.6% | $3.88M-68.8% | $12.44M-40.7% | ||
| $5.36M-5.7% | $5.69M+2.6% | $5.54M+13.2% | $4.9M-37.0% | $7.77M-40.5% | ||
| $458.02M+29.5% | $353.74M-40.4% | $593.07M-0.9% | $598.18M+22.9% | $486.55M+9.7% | ||
| —— | $0-100% | $48.16M-50.0% | $96.32M-33.3% | $144.48M-25.0% | ||
| —— | —— | —— | —— | $0— | ||
| $8.45M-16.1% | $10.07M+53.7% | $6.55M+7.8% | $6.08M+4.2% | $5.84M+46.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | -$4.8M-46.6% | -$3.27M-87.4% | -$1.75M-691% | -$220.75K-117% | ||
| $9.15M+4.0% | $8.81M-3.3% | $9.11M+39.7% | $6.52M+159% | $2.52M+165% | ||
| —— | —— | —— | -$635.71M-223% | -$196.98M-96.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Novavax generate?
- Novavax (NVAX) generated -$384.9M in operating cash flow over the trailing twelve months.
- What is Novavax's free cash flow?
- After $5.4M of capital expenditures, Novavax's free cash flow was -$389.7M over the trailing twelve months, down 288.4% year over year.
- Where does Novavax's cash flow data come from?
- Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
